GleamWall
中文EN

KALA KALA BIO, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1479419 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY72.9%
TTM EPS YoY196.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-345.3%
ROA-43.2%
ROIC (approx.)-1,688.4%
Asset turnover—

Leverage & solvency

Liabilities / assets14.5%
Debt / equity0.00x
Current ratio6.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.97x
Accruals ratio42.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$59,000$61,000$366,000$6.13M$6.23M$6.05M$5.26M$5.17M
SG&A expense$1.66M$1.74M$9.86M$4.53M$4.64M$4.59M$4.20M$4.40M
Operating income-$1.72M-$1.80M-$10.22M-$7.24M-$11.03M-$10.67M-$9.46M-$9.99M
Interest expense——$141,000$963,000$1.08M$1.09M$1.39M$1.48M
Net income-$1.58M-$1.62M$686,000-$7.56M-$11.15M-$8.95M-$8.18M-$8.95M
EBITDA——-$10.17M-$7.11M-$10.96M-$10.60M-$9.39M-$9.93M
EPS (basic)-21.32-0.14—-1.07-85.64-70.49—-1.93
EPS (diluted)-21.32-0.14—-1.07-85.64-70.49—-1.93
Weighted avg. shares (diluted)74,15911.87M—7.04M130,262126,917—4.63M
Balance sheet
Cash & equivalents$229,000$1.76M$7.56M$21.10M$31.94M$42.22M$51.18M$49.20M
Short-term investments$7.00M$7.00M——————
Current assets$10.58M$12.32M$9.49M$24.27M$33.66M$45.72M$52.80M$51.28M
PP&E, net———$603,000$657,000$695,000$749,000$762,000
Total assets$10.58M$12.32M$9.49M$25.02M$36.05M$48.25M$55.48M$54.08M
Current liabilities$1.54M$1.56M$2.49M$32.57M$16.02M$22.98M$16.96M$23.87M
Short-term debt———$28.41M$9.51M$15.50M$10.34M$17.98M
Long-term debt———$26.95M$18.79M$15.12M$20.10M$17.16M
Total debt———$55.36M$28.30M$30.62M$30.44M$35.14M
Total liabilities$1.54M$1.56M$2.49M$33.69M$39.26M$42.54M$43.15M$47.22M
Shareholders' equity$9.04M$10.76M$7.00M-$8.66M-$3.21M$5.71M$12.33M$6.86M
Net debt———$34.26M-$3.65M-$11.60M-$20.74M-$14.06M
Shares outstanding19.34M18.59M556,9957.43M6.68M6.45M6.09M4.61M
Cash flow statement
Operating cash flow-$1.53M-$2.90M-$4.56M-$10.88M-$16.56M-$8.82M-$4.60M-$4.72M
Investing cash flow$0-$7.00M$0$1,000——-$69,000-$90,000
Financing cash flow$0$4.10M-$8.98M$30,000-$2.53M-$135,000$6.65M-$180,000
Depreciation & amortization——$54,000$128,000$67,000$68,000$69,000$63,000
Stock-based compensation-$136,000-$471,000$401,000$2.04M$2.24M$2.31M$2.09M$2.04M

Free plan shows the latest 8 periods; Pro shows all 42 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.